New bipartisan legislation in the U.S. Senate would “would provide certainty to hospitals participating in the 340B drug discount program during the COVID-19 public health emergency,” its
…
The Health Resources and Services Administration (HRSA) has announced that, in
…The U.S. Department of Health and Human Services (HHS) lacks “reasonable assurance” that states and healthcare providers are complying with the prohibition against subjecting drug manufacturers to payment of duplicate 340B discounts
…Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of
…The Health Resources and Services Administration’s (HRSA) oversight of 340B private, nonprofit hospitals should be significantly strengthened, the Government Accountability Office (GAO) found in a report released
…The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts
…The Health Resources and Services Administration (HRSA) announced this morning that it has awarded the 340B Prime Vendor Agreement to Apexus LLC after a competitive bid process.
“The 340B Prime Vendor
…Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.
Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds
…*Sign up for news summaries and alerts from 340B Report
